Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 4/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 10/20 | 0.48 |
| ▸ | EGLN1 | Q9GZT9 | 6/20 | 0.47 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3727894 | 0.91 | EGLN1 (0.53) | EGLN3HIF1AEGLN1EGLN2L3MBTL1 | |
| SCHEMBL19406562 | 0.85 | EGLN3 (0.41) | EGLN3HIF1AEGLN1L3MBTL1MEN1 | |
| SCHEMBL3730753 | 0.85 | EGLN1 (0.53) | EGLN3HIF1AEGLN1EGLN2 | |
| SCHEMBL1967854 | 0.85 | EGLN3 (0.52) | EGLN3HIF1AEGLN1EGLN2 | |
| SCHEMBL1586247 | 0.83 | EGLN1 (0.61) | EGLN3HIF1AEGLN1EGLN2MEN1 | |
| SCHEMBL1585787 | 0.83 | HIF1A (0.53) | EGLN3HIF1AEGLN1 | |
| SCHEMBL1964633 | 0.82 | MAPT (0.40) | L3MBTL1MEN1KMT2A | |
| SCHEMBL1968417 | 0.80 | EGLN3 (0.44) | EGLN3HIF1AEGLN1EGLN2 | |
| SCHEMBL1966718 | 0.80 | EGLN1 (0.50) | EGLN3HIF1AEGLN1EGLN2 | |
| SCHEMBL1586485 | 0.79 | EGLN1 (0.47) | EGLN3HIF1AEGLN1EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2334682-B1 | PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS | FIBROGEN INC (US) | 2017-10-04 | — | — | EP | claimed |
| US-20100047367-A1 | COMPOUNDS AND METHODS FOR THEIR USE | FIBROGEN, INC. | 2010-02-25 | — | — | US | claimed |
| EP-2334682-B1 | PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS | FIBROGEN INC (US) | 2017-10-04 | — | — | EP | disclosed |
| EP-2334682-B1 | PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS | FIBROGEN INC (US) | 2017-10-04 | — | — | EP | disclosed |
| US-8217043-B2 | Compounds and methods for their use | FIBROGEN, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-8217043-B2 | Compounds and methods for their use | FIBROGEN, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| WO-2010022240-A1 | PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS | FIBROGEN, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20100047367-A1 | COMPOUNDS AND METHODS FOR THEIR USE | FIBROGEN, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100047367-A1 | COMPOUNDS AND METHODS FOR THEIR USE | FIBROGEN, INC. | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100047367-A1 | COMPOUNDS AND METHODS FOR THEIR USE | HIF1AN, HIF1A, EGLN3 | EGLN3 3/4885HIF1A 2/4885EGLN1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.